دورية أكاديمية
The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.
العنوان: | The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults. |
---|---|
المؤلفون: | Marcovecchio ML; Department of Paediatrics, University of Cambridge, Cambridge, UK. mlm45@medschl.cam.ac.uk.; Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. mlm45@medschl.cam.ac.uk., Hendriks AEJ; Department of Paediatrics, University of Cambridge, Cambridge, UK.; Department of Paediatric Diabetes and Endocrinology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Delfin C; Department of Pharmacometrics, Novo Nordisk A/S, Søborg, Denmark., Battelino T; Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Danne T; Centre for Paediatric Endocrinology, Diabetology, and Clinical Research, Auf Der Bult Children's Hospital, Hannover, Germany., Evans ML; Wellcome MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Johannesen J; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Kaur S; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Knip M; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Pediatric Research Center, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland., Overbergh L; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium., Pociot F; Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Paediatrics, Copenhagen University Hospital, Herlev, Denmark; Institute of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark., Todd JA; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Van der Schueren B; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium., Wicker LS; Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Peakman M; Immunology & Inflammation Research Therapeutic Area, Sanofi, MA, USA., Mathieu C; Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. |
مؤلفون مشاركون: | INNODIA consortium |
المصدر: | Diabetologia [Diabetologia] 2024 Jun; Vol. 67 (6), pp. 995-1008. Date of Electronic Publication: 2024 Mar 22. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Berlin Springer Verlag |
مواضيع طبية MeSH: | Diabetes Mellitus, Type 1*/diagnosis , Diabetes Mellitus, Type 1*/blood , Diabetes Mellitus, Type 1*/epidemiology , C-Peptide*/blood , Autoantibodies*/blood , Glycated Hemoglobin*/metabolism, Humans ; Adolescent ; Child ; Male ; Female ; Adult ; Young Adult ; Child, Preschool ; Blood Glucose/metabolism ; Cohort Studies ; Infant ; Europe/epidemiology ; Middle Aged ; Insulin-Secreting Cells/metabolism |
مستخلص: | Aims/hypothesis: Type 1 diabetes is an heterogenous condition. Characterising factors explaining differences in an individual's clinical course and treatment response will have important clinical and research implications. Our aim was to explore type 1 diabetes heterogeneity, as assessed by clinical characteristics, autoantibodies, beta cell function and glycaemic outcomes, during the first 12 months from diagnosis, and how it relates to age at diagnosis. Methods: Data were collected from the large INNODIA cohort of individuals (aged 1.0-45.0 years) newly diagnosed with type 1 diabetes, followed 3 monthly, to assess clinical characteristics, C-peptide, HbA Results: The study population included 649 individuals (57.3% male; age 12.1±8.3 years), 96.9% of whom were positive for one or more diabetes-related antibodies. Baseline (IQR) fasting C-peptide was 242.0 (139.0-382.0) pmol/l (AUC 749.3 [466.2-1106.1] pmol/l × min), with levels increasing with age (p<0.001). Over time, C-peptide remained lower in participants aged <10 years but it declined in all age groups. In parallel, glucose levels progressively increased. Lower baseline fasting C-peptide, BMI SD score and presence of diabetic ketoacidosis at diagnosis were associated with lower stimulated C-peptide over time. HbA Conclusions/interpretation: In this large cohort with newly diagnosed type 1 diabetes, we identified age-related differences in clinical and biochemical variables. Of note, C-peptide was lower in younger children but there were no main age differences in its rate of decline. (© 2024. The Author(s).) |
References: | Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74. (PMID: 30528100) Diabetes. 2022 Jul 1;71(7):1591-1596. (PMID: 35499624) Diabetes Care. 2022 Apr 1;45(4):871-879. (PMID: 35147706) Lancet Diabetes Endocrinol. 2023 Apr;11(4):251-260. (PMID: 36958868) Diabetologia. 2020 Jun;63(6):1258-1267. (PMID: 32172310) Lancet Diabetes Endocrinol. 2021 Oct;9(10):671-680. (PMID: 34481558) Diabetes Care. 2013 Nov;36(11):3454-9. (PMID: 23990516) Diabetes Care. 2013 Dec;36(12):4030-5. (PMID: 24130350) Diabetes Metab Res Rev. 2013 Jan;29(1):85-9. (PMID: 23081842) Pediatr Diabetes. 2022 Dec;23(8):1270-1276. (PMID: 36537523) PLoS One. 2013 Jun 06;8(6):e64683. (PMID: 23762245) Diabetes Care. 2016 Oct;39(10):1664-70. (PMID: 27422577) Diabetes. 2008 Nov;57(11):3152-5. (PMID: 18694972) Diabetes. 2014 Feb;63(2):739-48. (PMID: 24089509) Diabetes Care. 2009 Oct;32(10):1839-44. (PMID: 19587365) Diabetes. 2014 Nov;63(11):3835-45. (PMID: 24939426) Diabetes Res Clin Pract. 2021 May;175:108838. (PMID: 33901625) Diabetologia. 2001 Jan;44(1):3-15. (PMID: 11206408) Pediatr Diabetes. 2010 Jun;11(4):218-26. (PMID: 19708904) Trials. 2022 May 18;23(1):414. (PMID: 35585600) Diabetes. 2012 Aug;61(8):2066-73. (PMID: 22688329) Diabetes Care. 2010 Jun;33(6):1206-12. (PMID: 20508230) Diabetologia. 2003 Mar;46(3):420-5. (PMID: 12687342) Eur J Clin Nutr. 1990 Jan;44(1):45-60. (PMID: 2354692) JAMA Pediatr. 2022 Dec 1;176(12):1248-1259. (PMID: 36215053) Front Med (Lausanne). 2022 Jul 12;9:932086. (PMID: 35903316) Lancet Diabetes Endocrinol. 2022 Nov;10(11):763-765. (PMID: 36202117) Diabetologia. 2012 Dec;55(12):3359-68. (PMID: 22990715) Diabetes Care. 2015 Mar;38(3):476-81. (PMID: 25519448) Diabetes Res Clin Pract. 2013 May;100(2):203-9. (PMID: 23529064) Lancet Diabetes Endocrinol. 2022 Nov;10(11):786-794. (PMID: 36202118) Diabetes. 2022 Apr 1;71(4):610-623. (PMID: 35316839) Nat Rev Endocrinol. 2023 Sep;19(9):542-554. (PMID: 37337007) Horm Res. 2002;58 Suppl 1:66-71. (PMID: 12373017) Diabetes Care. 2023 Jan 1;46(Suppl 1):S19-S40. (PMID: 36507649) Diabet Med. 2021 Dec;38(12):e14712. (PMID: 34614253) Diabetes Care. 2008 Jul;31(7):1392-6. (PMID: 18356404) Diabetes. 2023 Sep 1;72(9):1289-1296. (PMID: 37368990) Diabetes Care. 2020 Jan;43(1):5-12. (PMID: 31753960) Lancet Diabetes Endocrinol. 2023 Jul;11(7):465-473. (PMID: 37290465) Diabetes Care. 2009 Aug;32(8):1384-90. (PMID: 19435955) Diabetes Care. 2018 Jul;41(7):1486-1492. (PMID: 29880650) Diabetes Care. 2020 Jan;43(1):169-177. (PMID: 31558544) Lancet. 2023 Jun 24;401(10394):2149-2162. (PMID: 37030316) JAMA Netw Open. 2023 Jun 1;6(6):e2321281. (PMID: 37389869) Clin Exp Immunol. 2022 Dec 15;210(2):151-162. (PMID: 36181724) |
معلومات مُعتمدة: | 115797 Innovative Medicines Initiative |
فهرسة مساهمة: | Keywords: Age; Beta cell function; C-peptide; Prevention; Subgroups; Treatment; Type 1 diabetes |
المشرفين على المادة: | 0 (C-Peptide) 0 (Autoantibodies) 0 (Glycated Hemoglobin) 0 (Blood Glucose) |
تواريخ الأحداث: | Date Created: 20240322 Date Completed: 20240429 Latest Revision: 20240502 |
رمز التحديث: | 20240502 |
مُعرف محوري في PubMed: | PMC11058619 |
DOI: | 10.1007/s00125-024-06124-5 |
PMID: | 38517484 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!